XML 26 R52.htm IDEA: XBRL DOCUMENT
v2.4.0.6

REVENUE (Details) (USD $) | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2012 Collaboration arrangement for development and commercialization of oral rotavirus strain Glaxo Rotarix | Dec. 31, 2011 Collaboration arrangement for development and commercialization of oral rotavirus strain Glaxo Rotarix | Dec. 31, 2010 Collaboration arrangement for development and commercialization of oral rotavirus strain Glaxo Rotarix | Apr. 30, 2008 Collaboration arrangement for development and commercialization of oral rotavirus strain Pfizer Rindopepimut | Dec. 31, 2010 Collaboration arrangement for development and commercialization of oral rotavirus strain Pfizer Rindopepimut | Dec. 31, 1995 License agreements Cincinnati Children's Hospital Medical Center Rotarix | Dec. 31, 2010 License agreements Duke University and Thomas Jefferson University Rindopepimut | May 31, 2005 Royalty Agreement PRF Rotarix | Dec. 31, 2012 Royalty Agreement PRF Rotarix Subsequent event
REVENUE |  |  |  |  |  |  |  |  |  |  |  |
Percentage of license fee payable on net royalties received |  |  |  |  |  |  |  |  | 30.00% |  |  |
Percentage of interest in net royalties sold |  |  |  |  |  |  |  |  |  |  | 70.00% |
Period for right to negotiate to extend the agreement term |  |  |  |  |  |  |  |  |  |  |  | 120 days
Product royalty revenue | $ 10,775,000 | $ 9,119,000 | $ 6,386,000 | $ 10,800,000 | $ 9,100,000 | $ 6,400,000 |  |  |  |  |  |
Product royalty expense | 10,775,000 | 9,119,000 | 12,077,000 | 10,800,000 | 9,100,000 | 6,400,000 |  | 5,700,000 |  |  |  |
Upfront fee received |  |  |  |  |  |  | 40,000,000 |  |  |  |  |
Equity investment |  |  |  |  |  |  | 10,000,000 |  |  |  |  |
Product development and licensing agreement revenue | 146,000 | 110,000 | 40,187,000 |  |  |  |  | 39,900,000 |  |  |  |
Reimbursable costs |  |  |  |  |  |  |  | 800,000 |  |  |  |
Sublicense fees paid to Duke University and Thomas Jefferson University |  |  |  |  |  |  |  |  |  | $ 6,900,000 |  |

X
- Definition Represents the amount received by the entity for the right to participate in a collaborative arrangement. + References No definition available. + Details
Name: | cldx_AmountReceivedForRightToParticipateInCollaborativeArrangement
Namespace Prefix: | cldx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of interest in net royalties sold. + References No definition available. + Details
Name: | cldx_PercentageOfInterestInNetRoyaltiesSold
Namespace Prefix: | cldx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of license fee payable to third party on net royalties received. + References No definition available. + Details
Name: | cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived
Namespace Prefix: | cldx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period for right to negotiate for extension of the agreement term under certain circumstances. + References No definition available. + Details
Name: | cldx_PeriodForRightToNegotiateForExtensionOfAgreementTermUnderCertainCircumstances
Namespace Prefix: | cldx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents revenue from product development and licensing agreements. + References No definition available. + Details
Name: | cldx_RevenueFromProductDevelopmentAndLicensingAgreements
Namespace Prefix: | cldx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the value of stock sold as an equity investment to obtain the right to participate in a collaborative arrangement. + References No definition available. + Details
Name: | cldx_StockIssuedDuringPeriodValueIssuedForCollaborativeArrangement
Namespace Prefix: | cldx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cost associated with reimbursable income. This occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 + Details
Name: | us-gaap_CostOfReimbursableExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration